Business
This Company Is About to Flood the U.S. With Cheap HIV Drugs
- India’s Laurus Labs preparing to enter U.S. with HIV generics
- Patents on key branded medicines to start expiring soon
This article is for subscribers only.
Among the coconut plantations and beaches of South India, a factory the size of 35 football fields is preparing to churn out billions of generic pills for HIV patients and flood the U.S. market with the low-cost copycat medicines.
U.S. patents on key components for some important HIV therapies are poised to expire starting in December and Laurus Labs Ltd. -- the Hyderabad, India-based company which owns the facility -- is gearing up to cash in.